

## CREATININE

COD 12502 10 x 50 mL

Only for *in vitro* use in the clinical laboratoryCREATININE  
JAFFÉ COMPENSATED

## INTENDED USE

Reagent for the measurement of creatinine concentration in human serum, plasma or urine. The obtained values are useful as an aid in diagnosis and treatment of renal diseases.

This reagent is for use in the BioSystems A25 and A15 analyzers or in other analyzer with similar performance characteristics.

## CLINICAL SIGNIFICANCE

Creatinine is a catabolic end product of creatine (or phosphocreatine). The amount produced each day is related to the muscle mass. Creatinine is freely filtered by the glomerulus (small amounts are reabsorbed and are also secreted by the renal tubules).

Creatinine measurement is used almost exclusively in the assessment of kidney function (impaired renal perfusion, loss of functioning nephrons) and in the monitoring renal dialysis<sup>1,2</sup>.

Clinical diagnosis should not be made on the findings of a single test result, but should integrate both clinical and laboratory data.

## PRINCIPLE OF THE METHOD

Creatinine in the sample reacts with picrate in alkaline medium forming a coloured complex (Jaffé method). The complex formation rate is measured in a short period to avoid interferences<sup>3,4</sup>. Serum and plasma samples contain proteins that react in a non specific way; nevertheless, the results can be corrected subtracting a fixed value. The use of this correction is known as the Jaffé method compensated<sup>5,6</sup>.

## CONTENTS AND COMPOSITION

A. Reagent. 5 x 50 mL. Sodium hydroxide 0.4 mol/L, detergent.

**WARNING: H315: Causes skin irritation. H319: Causes serious eye irritation. P280: Wear protective gloves/protective clothing/eye protection/face protection. P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P332+P313: If skin irritation occurs: Get medical advice/attention.**

B. Reagent. 5 x 50 mL. Picric acid 25 mmol/L.

For further warnings and precautions, see the product safety data sheet (SDS).

## STORAGE AND STABILITY

Store at 2-30°C.

Components are stable once opened until the expiry date marked in the label if they are stored well closed and care is taken to prevent contamination during their use.

On board stability: Reagents open and kept in the refrigerated compartment of the analyzer at 2-8°C are stable 2 weeks.

Indications of deterioration: Reagents: RA is a NaOH solution with high concentration. In some storage conditions (i.e. storage at a lower temperature than indicated) a precipitate may appear in the vial that will not affect the reagent performance and will disappear with a slight rotation of the vial before carrying out the analysis. RB, presence of particulate material, turbidity. Absorbance of the blank over the limit indicated in "Test Parameters".

## ADDITIONAL MATERIALS REQUIRED (NOT PROVIDED)

Biochemistry Calibrator (BioSystems cod. 18011) or Biochemistry Calibrator Human (BioSystems cod. 18044).

## REAGENT PREPARATION

Reagents are provided ready to use.

## SAMPLES

Serum, plasma or urine collected by standard procedures. Heparin, EDTA, oxalate and fluoride may be used as anticoagulants.

Creatinine in serum/plasma is stable up to 7 days at 20-25 °C, 7 days at 2-8 °C or 3 months at -20 °C. Creatinine in urine is stable up to 2 days at 20-25 °C, 6 days at 2-8 °C or 6 months at -20 °C<sup>7</sup>.

## CALIBRATION

A reagent blank should be done every day and a calibration at least every 7 days, after reagent lot change or as required by quality control procedures.

## QUALITY CONTROL

It is recommended to use the Biochemistry Control Serum level I (cod. 18005, cod. 18009 and cod. 18042) and II (cod. 18007, cod. 18010 and cod. 18043) and the Biochemistry Control Urine (cod. 18054 and cod. 18066) to verify the accuracy of the measurement procedure.

Each laboratory should establish its own internal Quality Control scheme and procedures for corrective action if control results are not within the acceptable limits.

## REFERENCE VALUES

Serum and plasma<sup>8</sup>:

Men: 0.7 - 1.2 mg/dL = 62 - 106 µmol/L  
Women: 0.5 - 0.9 mg/dL = 44 - 80 µmol/L

Urine<sup>1</sup>:

Men: 14 - 26 mg/kg/24-h = 124 - 230 µmol/kg/24-h  
Women: 11 - 20 mg/kg/24-h = 97 - 177 µmol/kg/24-h

These ranges are given for orientation only; each laboratory should establish its own reference ranges.

## METROLOGICAL CHARACTERISTICS

The metrological characteristics described below have been obtained using an A25 analyzer. Results are similar with A15.

- Detection limit: 0.1 mg/dL = 8.57 µmol/L.
- Linearity limit: 20 mg/dL = 1768 µmol/L.

– Precision:

Serum. Mean (mg/dL) / (µmol/L)	Repeatability (CV)%	Reproducibility (CV)%
1.12 mg/dL = 99.1 µmol/L	4.2 %	5.7 %
3.61 mg/dL = 319 µmol/L	2 %	4.6 %
15.3 mg/dL = 1357 µmol/L	0.8 %	3.9 %

Urine. Mean (mg/dL) / (µmol/L)	Repeatability (CV)%	Reproducibility (CV)%
69 mg/dL = 6108 µmol/L	2.1 %	2.7 %
169 mg/dL = 14913 µmol/L	1.1 %	1.8 %
746 mg/dL = 66062 µmol/L	0.5 %	1.7 %

For repeatability and reproducibility studies, samples were measured on three different analyzers during five days, one run per day and five replicates per run.

– Trueness: Results obtained with this reagent did not show systematic differences when compared with reference reagents. Details of the comparison experiments are available on request.

## LIMITATIONS OF THE PROCEDURE

– Interferences: Bilirubin (up to 10 mg/dL), hemolysis (hemoglobin up to 500 mg/dL), lipemia (triglycerides up to 600 mg/dL) and protein and ketonic bodies do not interfere. High concentration of reducing compounds may interfere. Other drugs and substances may interfere<sup>9</sup>.

## NOTE

- For measurement in serum or plasma, introduce corrective value for the reaction of nonspecific proteins as a factor in the equation of the instrument  $y = ax + b$ , where  $a = 1.1$  and  $b = -0.565$  (mg/dL), or  $a = 1.1$  and  $b = -50$  (µmol/L)<sup>5,6</sup>.

## BIBLIOGRAPHY

- Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 6th ed. Rifai N, Horvath AR, Wittwer CT. WB Saunders Co, 2018.
- Friedman and Young. Effects of disease on clinical laboratory tests, 4th ed. AACC Press, 2001.
- Bartels H, Böhmer M. Eine mikromethode zur kreatininbestimmung. Clin Chim Acta 1971; 32: 81-85.
- Fabiny DL, Ertlingshausen G. Automated reaction-rate method for determination of serum creatinine with CentrifChem. Clin Chem 1971; 17: 696-700.
- Weber JA, Van Zanten AP. Interferences in current methods for measurements of creatinine. Clin Chem 1991; 37: 695-700.
- Peake M, Whiting M. Measurement of serum creatinine-current status and future goals. Clin Biochem 2006;27:173-184.
- World Health Organization (WHO). Use of anticoagulants in diagnostic laboratory investigations. Document WHO/DIL/LAB/99.1, Rev.2; 2002.
- Mazzachi BC, Peake MJ, Ehrhardt V. Reference range and method comparison studies for enzymatic and Jaffé creatinine assays in plasma and serum and early morning urine. Clin Lab 2000;46:53-55.
- Young DS. Effects of drugs on clinical laboratory tests, 5th ed. AACC Press, 2000.

## TEST PARAMETERS (Note 1)

R1: Use Reagent A.

R2: Use Reagent B.

	A25	A15
GENERAL		
Name	CREATININE	CREATININE
Sample type	SER / URI	SER / URI
Analysis mode	fixed-time bir.	fixed-time bir.
Units	mg/dL	mg/dL
Turbidimetry test	No	No
Decimals	2	2
Type of reaction	increasing	increasing
PROCEDURE		
Reading mode	monoch.	monoch.
Main filter	505	505
Reference filter	-	-
Sample	30	30
Vol. R1	150	150
Vol. R2	150	150
Washing	1.2	1.2
Reading 1 (cycle)	23	15
Reading 2 (cycle)	28	18
Reagent 2 (cycle)	21	13
Predilution factor	- / 50	- / 50
CALIBRATION AND BLANK		
Calibration type	multiple	multiple
Number of calibrators	-	-
Calibration curve	-	-
OPTIONS		
Blank absorbance limit	0.350	0.350
Kinetic blank limit	-	-
Linearity limit	20 / 1000	20 / 1000
Substrate depletion	-	-

